Reslizumab

Drug Profile

Reslizumab

Alternative Names: Anti-interleukin-5 monoclonal antibody - Celltech/Schering-Plough; CDP 835; CEP-38072; CINQAERO; CINQAIR; Cinquil; CTx 55700; DCP 835; SCH 5570; SCH 55700; TRFK-5

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celltech R&D; Schering-Plough
  • Developer Allergy and Asthma Clinical Research; Celltech R&D; Teva Pharmaceutical Industries
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Phase III Sinusitis
  • No development reported Oesophagitis

Most Recent Events

  • 20 Jul 2017 The National Institute for Health and Care Excellence recommends reslizumab for Eosinophilic Asthma
  • 07 Jul 2017 The German Federal Joint Committee issues added benefit opinion for reslizumab for Asthma
  • 13 Mar 2017 Teva initiates a phase III open-label extension trial in Asthma (In adolescents, In adults, In the elderly) in USA, Belgium, Czech Republic, Hungary (NCT03052725; EudraCT2016-004661-23)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top